Biomarkers for Alzheimer's Disease Diagnosis and Treatment

ChangeBridge: Patent Apps - Peptides (C07K)

Published April 2nd, 2026

Detected April 2nd, 2026

Summary

USPTO published patent application US20260091025A1 by Electrophoretics Limited covering biomarker panels for Alzheimer's disease diagnosis and treatment. The application claims panels including PP1 regulatory subunit 14A, CNPase, and phosphorylated tau proteins, along with methods for diagnosing and staging neurocognitive disorders using casein kinase 1 delta inhibitors.

View original document View source feed page

What changed

Electrophoretics Limited filed patent application US20260091025A1 disclosing biomarker panels for Alzheimer's disease diagnosis, staging, and treatment assessment. The claimed biomarkers include protein phosphatase 1 regulatory subunit 14A (PPP1R14A), 2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNPase), and phosphorylated tau proteins or fragments thereof. The application further covers methods using casein kinase 1 delta inhibitors in combination with these biomarkers. The biomarkers are shown to be elevated in brains at advanced Braak stages V/VI and regulated in CSF of AD subjects compared to non-AD controls.

Patent applications do not impose regulatory compliance obligations. Healthcare and pharmaceutical entities developing Alzheimer's diagnostics or treatments should review the disclosed biomarker combinations and methods to assess potential freedom-to-operate considerations or licensing opportunities. The application filing date was July 29, 2025.

Source document (simplified)

← USPTO Patent Applications

BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE

Application US20260091025A1 Kind: A1 Apr 02, 2026

Assignee

Electrophoretics Limited

Inventors

Ian Hugo PIKE, Malcolm Andrew WARD, Claire Louise RUSSELL, Vikram MITRA

Abstract

The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V/VI) and/or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and/or regulated in response to two casein kinase 1 delta inhibitors.